HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
eJNxgWSFe41J8hvk